Journal
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
Volume 102, Issue 17, Pages 7565-7575Publisher
SPRINGER
DOI: 10.1007/s00253-018-9155-6
Keywords
Alzheimer's disease (AD); GLP-1; MG1363-pMG36e-GLP-1; TLR-4; COX-2
Categories
Funding
- National Natural Science Foundation of China [31560264, 81503364]
- Excellent Youth Foundation of JiangXi Scientific Committee [20171BCB23028]
- Science and Technology Plan of Jianxi Health Planning Committee [20175526]
Ask authors/readers for more resources
The anti-obesity drug GLP-1 has been proven to have an impact on central nervous system, while its extremely short half-life greatly limited its use. In this study, our group constructed two engineering strains MG1363-pMG36e-GLP-1 and VNP20009-pLIVE-GLP-1 to continuously express GLP-1, and supplementation of these strains, especially MG1363-pMG36e-GLP-1, had significantly restored the spatial learning and memory impairment of mice caused by LPS (p < 0.05), suppressed glia activation and A beta accumulation, and downregulated inflammatory expressions of COX-2, TLR-4, TNF-a, and IL-1 beta. In addition, MG1363-pMG36e-GLP-1 had significantly blocked the translocation of NF-kappa B signal and inhibited the phosphorylation of redox-sensitive cytoplasmic signalings of MAPKs and PI3K/AKT. These data suggest that MG1363-pMG36e-GLP-1 could be used as a safe and effective nonabsorbed oral treatment for neuroinflammation-related diseases such as Alzheimer's disease (AD).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available